Core Insights - The core viewpoint of the article highlights the strong financial performance of Yuan Da Pharmaceutical, with record revenue and net profit in the first half of 2025, driven by significant growth in its nuclear medicine segment [1] Financial Performance - Yuan Da Pharmaceutical reported a historical high revenue of approximately HKD 61.1 billion in the first half of 2025 [1] - The net profit for the same period reached around HKD 11.7 billion [1] Nuclear Medicine Segment - The nuclear medicine oncology treatment segment achieved revenue of approximately HKD 4.2 billion, representing a year-on-year growth of 106% [1] - The innovative nuclear medicine product, Yigan Tai, has maintained rapid growth in the domestic market [1] Regulatory Approvals - In July 2025, Yigan Tai received early approval from the US FDA for a new indication to treat unresectable hepatocellular carcinoma (HCC), making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1] Product Development - Yuan Da Pharmaceutical has established a robust product pipeline in the nuclear medicine field, with 15 innovative products in the research and registration phase [1] - The company has formed an integrated product matrix for diagnosis and treatment, positioning itself as the enterprise with the largest reserve of innovative drugs in the diagnostic and therapeutic RDC category entering Phase III clinical trials in China [1]
核药龙头远大医药上半年收入创新高，核药抗肿瘤诊疗板块收入翻倍